AUSTIN (KXAN) — In 2023, the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) ...
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...
EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...
Adults who are at risk of severe RSV are 75 years or older. Also, people between 60 and 74 years old who have chronic health ...
Respiratory Illness season is right around the corner and experts are urging parents to take action to protect their newborns ...
In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...
GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...
There’s about 270 different viruses that can infect humans, and in the fall and winter we're inside more where they can ...
Respiratory syncytial virus (RSV) is the leading cause of hospitalization in young children due to respiratory complications such as bronchiolitis and pneumonia.
It’s that time of year again when those most at risk of getting seriously ill from flu and Covid should sign up for their ...
As we enter cold and flu season, the medical community wants pregnant women to know it's now recommended they receive the RSV ...